Key Insights

Highlights

Treatment Research

1 treatments under study, led by Zero Minis Range Of Protein Substitutes In Tablet Form

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

Trial Status

Unknown1

Clinical Trials (1)

Research Network

Common Treatments

  • Zero Minis Range Of Protein Substitutes In Tablet Form1

Active Sponsors

  • Birmingham Women's and Children's NHS Foundation Trust1
  • Great Ormond Street Hospital for Children NHS Foundation Trust1
  • metaX Institut fuer Diatetik GmbH1

Top Investigators

Related Conditions

  • Alkaptonuria1
  • Tyrosinemia Type Ii1
  • Homocystine Metabolic Disorder1
  • Tyrosinemia Type I1
  • Tyrosinemia Type Iii1

Activity Timeline